Hydrogen Therapy Shows Promise for Rheumatoid Arthritis Treatment

Authors
Journal
Current Pharmaceutical Design
Year
DOI
10.2174/13816128113199990507
Study Type
clinical
Peer Reviewed
Yes
Country
Japan
Health Condition
Rheumatoid Arthritis
Body System
Musculoskeletal

TL;DR

Scientists found that a special type of hydrogen gas might help treat rheumatoid arthritis (a disease where your joints get inflamed and damaged) by reducing harmful chemicals in your body that cause swelling. This could be really useful because it might work even better when combined with regular arthritis medicines and could help catch the disease earlier.

Key Finding

Molecular hydrogen may selectively neutralize the most damaging type of reactive oxygen species (hydroxyl radicals) and reduce inflammation through specific cellular pathways involved in rheumatoid arthritis.

Summary

This article reviews how molecular hydrogen (H2) might help treat rheumatoid arthritis, a disease where the immune system attacks joints and causes inflammation. The authors explain that hydrogen gas may work by reducing harmful molecules called reactive oxygen species that fuel inflammation in RA, and suggest it could be used alongside standard treatments to potentially improve outcomes and prevent related heart disease.

Practical Takeaway

This is a review article discussing theoretical mechanisms rather than reporting new experimental results, so it does not provide direct evidence that hydrogen water helps RA patients. While the authors raise interesting possibilities about hydrogen's potential as an add-on therapy, actual clinical studies in humans would be needed to determine whether it offers real benefits for people with rheumatoid arthritis.

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory disease in which the progressive destruction of joint causes morbidity. It is also associated with an increased risk of atherosclerosis, which can result in cardiovascular disease and mortality. The therapeutic goal is to control the systemic inflammation to obtain not only the remission of symptoms, but also improve general state of health. Although recent biologic immunosuppressive therapies targeting pro-inflammatory cytokines have spawned a paradigm shift regarding the prognosis of RA, these therapies possess inherent side effects. Also, early diagnosis of the disease remains confounded by uncertainty. While the mechanisms responsible for the onset of RA remain unclear, reactive oxygen species (ROS) play a significant role in the pathogenesis of RA. ROS play a central role both upstream and downstream of NF-κB and TNFα pathways, which are located at the center of the inflammatory response. Among the ROS, the hydroxyl radical is the most harmful, and molecular hydrogen (H2) is a selective scavenger for this species. Recently, it has been shown that H2 is useful when administered along with the conventional therapy in RA as it acts to reduce oxidative stress in the patients. Especially in the early stage, H2 showed significant therapeutic potential, which also seemed to assist diagnosis and treatment decisions of RA. The possible expectations regarding the potential benefits of H2 by reducing the oxidative stress, resulting from inflammatory factors, are raised and discussed here. They include prevention of RA and related atherosclerosis, as well as therapeutic validity for RA.